Metastatic Gastric Cancer Clinical Trial
Official title:
Phase II Study of Metronomic Chemotherapy Using POLF Regimen in the Treatment of Advanced Gastric Cancer
phase II study of weekly metronomic chemotherapy using weekly Paclitaxel, Oxaliplatin, Leucovorin and 5-FU (POLF) in patients with advanced gastric cancer
About 80% of patients with advanced gastric cancer are diagnosed at an advanced stage with limited treatment options including systemic chemotherapy with or without radiation. Commonly used maximally tolerated dose (MTD) chemotherapy such as DCT, ECF, FOLFOX regimens induce responses in the range of 20 to 50% with median survival in the range of 10 to 12 months. Metronomic chemotherapy has been found to have more consistent anti-tumor effects through anti-angiogenic and immunomodulating effects. Preliminary clinical studies of weekly POLF have found very encouraging clinical activities and low overall toxicities in pancreatic cancer and gastric cancer. Here we conduct a formal clinical trial to determine the clinical efficacy and side effect profiles of this regimen in patients with advanced gastric cancer. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04618809 -
Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer
|
N/A | |
| Recruiting |
NCT02668380 -
An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer
|
N/A | |
| Completed |
NCT03121807 -
Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer
|
N/A | |
| Recruiting |
NCT04358354 -
Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer
|
Phase 3 | |
| Completed |
NCT01099527 -
A Trial of RAD001/Capecitabine in Refractory Gastric Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00253370 -
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
|
Phase 2 | |
| Recruiting |
NCT02002195 -
Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
|
||
| Recruiting |
NCT06008925 -
Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05714124 -
Liver Embolization Approaches for Tumor Management
|
||
| Recruiting |
NCT03154983 -
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04263870 -
Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
|
Phase 2 | |
| Active, not recruiting |
NCT01359397 -
Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT04739202 -
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)
|
Phase 2 | |
| Completed |
NCT03409848 -
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT05859477 -
Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT05955833 -
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
|
Phase 1 | |
| Terminated |
NCT01528501 -
Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)
|
Phase 2 | |
| Completed |
NCT03751761 -
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05024812 -
Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03614013 -
Resistance to Immunotherapy in Gastric Cancer
|